EX-99.1

This presentation contains forward-looking statements, including, but not limited to, statements regarding

the terms, timing, conditions to and anticipated completion of the proposed merger; the expected

ownership of the combined company and the composition of the combined company’s board of directors

and management team; the anticipated distribution to OncoGenex Pharmaceuticals, Inc. (OngoGenex)

stockholders of contingent value rights (CVRs) and the terms, timing and value of such CVRs; the timing of

planned clinical development activities of cytisine; the projected path toward potential regulatory approval;

the safety, efficacy and commercial potential of cytisine; plans, objectives, expectations and intentions with

respect to future operations. All statements other than statements of historical fact are statements that

could be deemed forward-looking statements. Achieve Life Science, Inc. (Achieve) and/or OncoGenex may

not actually achieve the proposed merger, or any plans or product development goals in a timely manner, if

at all, or otherwise carry out the intentions or meet the expectations or projections disclosed in these

forward-looking statements. These statements are based on management's current expectations and

beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results

to differ materially from those described in the forward-looking statements, including, among others, the

failure of the Achieve or OncoGenex stockholders to approve the transaction; the failure of either party to

meet the closing conditions of the transaction; delays in completing the transaction and the risk that the

transaction may not be completed at all; the success of the combined businesses; operating costs and

business disruption during the pendency of and following the proposed merger; general business and

economic conditions; the need for and ability to obtain additional financing; the ability to source sufficient

amounts of cytisine

to meet commercial demand; and the risks associated with the process of developing,

obtaining regulatory approval for and commercializing drug candidates that are safe and effective for use

as human therapeutics. Achieve undertakes no obligation to update the forward-looking statements

contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be

required by applicable law.

Forward Looking Statements

This communication is being made in respect of the proposed merger involving OncoGenex

Pharmaceuticals, Inc. and Achieve Life Science, Inc. OncoGenex will file with the Securities and Exchange

Commission, or SEC, a current report on Form 8-K, which will include the merger agreement and related

documents. In addition, OncoGenex intends to file a registration statement on Form S-4 with the SEC,

which will contain a joint proxy statement/prospectus and other relevant materials, and plans to file with the

SEC other documents regarding the proposed transaction. The final joint proxy statement/prospectus will

be sent to the stockholders of OncoGenex and Achieve. The joint proxy statement/prospectus will contain

information about OncoGenex, Achieve, the proposed merger and related matters. STOCKHOLDERS

ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING ANY

AMENDMENTS OR SUPPLEMENTS) AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY

IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT

INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING A DECISION ABOUT

THE MERGER AND RELATED MATTERS. In addition to receiving the joint proxy statement/prospectus

and proxy card by mail, stockholders will also be able to obtain the joint proxy statement/prospectus, as

well as other filings containing information about OncoGenex, without charge, from the SEC’s website

(http://www.sec.gov) or, without charge, by directing a written request to:

OncoGenex Pharmaceuticals,

Inc., 19820 North Creek Parkway,

Suite 201, Bothell, WA 98011, Attention: Investor Relations or to

Achieve Life Science, Inc., 30 Sunnyside Avenue, Mill Valley, CA 94941, Attention: Rick Stewart.

Important Additional Information About

the Merger

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation

of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such

offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of

any such jurisdiction. No offering of securities in connection with the proposed merger shall be made

except by means of a prospectus meeting the requirements of Section

10 of the Securities Act of 1933, as

amended.

Participants in Solicitation

OncoGenex and its executive officers and directors may be deemed to be participants in the solicitation of

proxies from OncoGenex’s stockholders with respect to the matters relating to the proposed merger.

Achieve and its officers and directors may also be deemed a participant in such solicitation. Information

regarding OncoGenex’s executive officers and directors is available in OncoGenex’s proxy statement on

Schedule 14A, filed with the SEC on April 21, 2016. Information regarding any interest that OncoGenex,

Achieve or any of the executive officers or directors of OncoGenex or Achieve may have in the transaction

with Achieve will be set forth in the joint proxy statement/prospectus that OncoGenex intends to file with the

SEC in connection with its stockholder vote on matters relating to the proposed merger. Stockholders will

be able to obtain this information by reading the joint proxy statement/prospectus when it becomes

available.

Important Additional Information About

the Merger

Achieve Life Science, Inc. and OncoGenex Pharmaceuticals, Inc.

signed definitive merger agreement January 5, 2017

Upon completion of the merger, Achieve shareholders are

expected to own

75% and OGXI shareholders are expected to

own

25% of the combined company

OGXI shareholders are expected to receive contingent value

rights for 80% of defined consideration received related to

apatorsen

Board composition to be 4 designates of Achieve and 3

designates of OGXI

Merger expected to be completed in mid-2017 subject to OGXI

shareholder approval

About the Merger

Rick Stewart

Chairman & CEO

Chairman & CEO of Ricanto

CEO

Brabant

Pharma

(acquired

Zogenix)

Chairman & CEO of Huxley Pharma (acquired by BioMarin)

CEO of Amarin

Corp

Founder

CBO

SkyePharma

(acquired

Vectura)

John Bencich, MBA,

CPA

CFO

CFO of OncoGenex

CFO of Integrated Diagnostics

CFO of Allozyne

CFO

Trubion

Pharmaceuticals

(acquired

Emergent)

Cindy Jacobs,

PhD, MD

CMO

CMO of OncoGenex

CMO of Corixa

(acquired by GSK)

VP Clinical Development, CellPro

Anthony Clarke, PhD

CSO

CSO of Ricanto

CSO of Brabant

Pharma (acquired by Zogenix)

CSO of Huxley Pharma (acquired by BioMarin)

CSO

Amarin

Corp

Post-Merger Management Team

Achieve is a privately-held, specialty pharma company focused

on the development of cytisine

for smoking cessation

In-licensed

rights

cytisine

from

Sopharma

(excluding

Central

and Eastern Europe)

Cytisine

is approved in Central and Eastern Europe for smoking

cessation and sold through Sopharma

In-market exposure estimated in over 20 million patients

An extensive EMA-compliant PSUR/clinical safety database of 8.5

million patients

Safety and efficacy are further supported by two Phase 3 clinical

studies in over 2,000 patients published in NEJM

Overview: Achieve Life Science, Inc.

Nicotine addiction/smoking cessation = single most important public health issue globally

Market Opportunity

Smoking cessation is one of the most important public health

issues globally

Smoking is the #1 cause of preventable deaths worldwide

•

Tobacco consumption is responsible for cancers, cardiovascular, pulmonary

and GI diseases

More than 480,000 U.S. deaths annually from smoking-related disease

Smoking-related

healthcare

costs

the

U.S.

are

$170

billion

annually

Medicaid expenditures attributable to smoking-related diseases total

nearly $22 billion annually, representing 11% of all expenditures

Global smoking cessation market expected to reach $4.4 billion

by 2023

44+

million

smokers

U.S.

alone

(

15%

the

U.S.

population)

According to the Centers for Disease Control and Prevention (CDC),

nearly 70% of current smokers have expressed a desire to quit, 40%

attempted to quit in the past year, but only 6.2% succeeded

•

Cytisine

is a plant-based

alkyloid

found in

members of the

leguminosae

family

•

Partial agonist that binds

with high affinity to the

nicotinic

acetylcholine receptor

•

nicotinic receptor is

well-characterized in

addiction, interrupts

nicotine craving

Well

Characterized

MOA

•

Two Phase III trials;

2,050 patients, both

published in NEJM

•

10,000 patients in

clinical trials to-date

•

Excellent safety profile

•

8.5 million patients in

European PSUR Safety

database

Strong Ex-U.S.

Clinical and Safety

Profile

•

IND enabling studies

nearing completion

•

IND expected to be filed

in 2H 2017

•

Phase I fed/fasted &

repeat dose PK study

•

Phase 3 trial expected to

be initiated in 1H 2018

Defined U.S.

Regulatory Pathway

•

Oral product approved for

smoking cessation in

Central and Eastern

Europe

•

20 million patients

treated

•

Cost-effective

•

Demonstrated superiority

to nicotine replacement in

large, randomized trial

•

Similar efficacy to

varenicline, with potentially

less side effects

Market Experience

and Product

Opportunity

Cytisine: Product Overview

25-day cytisine dosing

regimen or matched

placebo

Cytisine

vs Placebo

6 & 12-month quit rates

confirmed by exhaled

carbon monoxide levels

Primary Endpoint

Double-blind, randomized, placebo-controlled; minimal behavioral support

Conducted in Poland with funding support from Medical Research Council,

Cancer Research UK, Wellcome

Foundation, University College London and

others

Cytisine

3.4 times more likely to result in smoking cessation after 12 months

(p=0.001)

Higher

than

studies

have

shown

for

varenicline

(2.3)

and

NRT

(1.3)

Overall adverse events between cytisine and placebo were similar with higher

GI events in cytisine

group

No Serious Adverse Events related to therapy

N=740

Heavy smokers

Aged 18 or over;

Randomized 1:1

Phase 3 Trial –

TASC (Cytisine

vs. Placebo)

N Engl

J Med; 365:13 Sept 29, 2011

25-day cytisine dosing

regimen or 8-week NRT

(patch and/or gum or

lozenge)

Cytisine vs. NRT

1, 2, 6-month quit rates

Primary Endpoint

Randomized, open-label, active-controlled, non-inferiority study design with

moderate behavioral support

Cytisine

compared to nicotine replacement therapy (NRT)

Conducted by University of Auckland and funded by Health Research Council,

New Zealand

Cytisine

1.43 times more likely than NRT to result in smoking cessation after 6

months (p=0.002)

Not only non-inferior to NRT, but deemed to be superior by investigators

No overall difference in adverse effects between cytisine and NRT

No Serious Adverse Effects related to therapy

N=1,310

Heavy smokers

Aged 18 or over;

Randomized 1:1

Phase 3 Trial –

CASCAID (Cytisine

vs. NRT)

N Engl

J Med; 371:25 Dec 18, 2014

Key findings

•

No apparent difference in efficacy between cytisine and varenicline

•

Cytisine

has an Relative Risk (“RR”) = 3.98; varenicline

= 2.24

•

Cytisine trials were conducted with minimal behavioral support, varenicline trials with behavioral support

•

Behavioral support can increase patient response by 10%-15%

•

Minimal behavioral support may have limited cytisine headline cessation rates

Cytisine

•

Pooled RR based on 2

published studies*

•

n=937

•

RR (CI

95%

) at longest

follow-up 3.98 (2.01-

7.87)

Varenicline

•

Pooled RR based on

27 published studies

•

N=12,625

•

RR (CI

%) longest

follow-up 2.24 (2.06-

2.43)

Cochrane Database Review: Cytisine

Efficacy Profile

Cahill

al.

Nicotine

receptor

partial

agonists

for

smoking

cessation.

Cochrane

Database

Systematic

Reviews

2016,

Issue 5.

Efficacy

Cytisine and varenicline are partial agonists at the

nicotinic acetylcholine

receptor

Activity at this receptor in the ventral tegmental area of the brain mediates

therapeutic effect

The two drugs have similar efficacy

Safety

Varenicline

interacts potently with a broader range of nicotinic receptors than cytisine

Action at these additional receptors may be associated with additional side effects

Site

Receptor

Cytisine

Varenicline

Brain

Periphery

MOA Differences between Cytisine

and

Varenicline

FDA directed U.S. regulatory pathway (meeting June 19, 2015)

File IND utilizing non-clinical data package (compliant with current

guidelines)

Conduct fed/fasted and repeat dose PK studies

Conduct Phase III study in the U.S.

Meet with EMA to agree on EU regulatory pathway

Meet with national regulators in Germany, Holland & Sweden

Determine whether existing MAA dossier is sufficient for MAA

submission

•

Include new non-clinical data

•

Include data from TASC and CASCAID Phase 3 trials

Potential to file an MAA with EMA with additional datasets

Anticipated Path to U.S. and EU

Regulatory Approval